161 related articles for article (PubMed ID: 38205637)
1. Synthesis and evaluation of 2,5-substituted pyrimidines as small-molecule gankyrin binders.
Kanabar D; Kane EI; Chavan T; Laflamme TM; Suarez E; Goyal M; Gupta V; Spratt DE; Muth A
Future Med Chem; 2024 Feb; 16(3):239-251. PubMed ID: 38205637
[No Abstract] [Full Text] [Related]
2. The oncoprotein gankyrin negatively regulates both p53 and RB by enhancing proteasomal degradation.
Higashitsuji H; Liu Y; Mayer RJ; Fujita J
Cell Cycle; 2005 Oct; 4(10):1335-7. PubMed ID: 16177571
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a small-molecule binder of the oncoprotein gankyrin that modulates gankyrin activity in the cell.
Chattopadhyay A; O'Connor CJ; Zhang F; Galvagnion C; Galloway WR; Tan YS; Stokes JE; Rahman T; Verma C; Spring DR; Itzhaki LS
Sci Rep; 2016 Apr; 6():23732. PubMed ID: 27046077
[TBL] [Abstract][Full Text] [Related]
4. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53.
Higashitsuji H; Higashitsuji H; Itoh K; Sakurai T; Nagao T; Sumitomo Y; Masuda T; Dawson S; Shimada Y; Mayer RJ; Fujita J
Cancer Cell; 2005 Jul; 8(1):75-87. PubMed ID: 16023600
[TBL] [Abstract][Full Text] [Related]
5. Synthetic Proteins Potently and Selectively Bind the Oncoprotein Gankyrin, Modulate Its Interaction with S6 ATPase, and Suppress Gankyrin/MDM2-Dependent Ubiquitination of p53.
Chapman AM; McNaughton BR
ACS Chem Biol; 2015 Aug; 10(8):1880-6. PubMed ID: 25955581
[TBL] [Abstract][Full Text] [Related]
6. Small-Molecule Gankyrin Inhibition as a Therapeutic Strategy for Breast and Lung Cancer.
Kanabar D; Goyal M; Kane EI; Chavan T; Kabir A; Wang X; Shukla S; Almasri J; Goswami S; Osman G; Kokolis M; Spratt DE; Gupta V; Muth A
J Med Chem; 2022 Jul; 65(13):8975-8997. PubMed ID: 35758870
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of human oncoprotein gankyrin in Zebrafish.
Kim SY; Hur W; Choi JE; Kim D; Wang JS; Yoon HY; Piao LS; Yoon SK
Exp Mol Med; 2009 Jan; 41(1):8-16. PubMed ID: 19287195
[TBL] [Abstract][Full Text] [Related]
8. Structural modification of the aryl sulfonate ester of cjoc42 for enhanced gankyrin binding and anti-cancer activity.
Kanabar D; Farrales P; Gnanamony M; Almasri J; Abo-Ali EM; Otmankel Y; Shah H; Nguyen D; El Menyewi M; Dukhande VV; D'Souza A; Muth A
Bioorg Med Chem Lett; 2020 Feb; 30(4):126889. PubMed ID: 31902711
[TBL] [Abstract][Full Text] [Related]
9. The crystal structure of gankyrin, an oncoprotein found in complexes with cyclin-dependent kinase 4, a 19 S proteasomal ATPase regulator, and the tumor suppressors Rb and p53.
Krzywda S; Brzozowski AM; Higashitsuji H; Fujita J; Welchman R; Dawson S; Mayer RJ; Wilkinson AJ
J Biol Chem; 2004 Jan; 279(2):1541-5. PubMed ID: 14573599
[TBL] [Abstract][Full Text] [Related]
10. Gankyrin, the 26 S proteasome, the cell cycle and cancer.
Mayer RJ; Fujita J
Biochem Soc Trans; 2006 Nov; 34(Pt 5):746-8. PubMed ID: 17052188
[TBL] [Abstract][Full Text] [Related]
11. Optimizing the aryl-triazole of cjoc42 for enhanced gankyrin binding and anti-cancer activity.
Kanabar D; Farrales P; Kabir A; Juang D; Gnanmony M; Almasri J; Torrents N; Shukla S; Gupta V; Dukhande VV; D'Souza A; Muth A
Bioorg Med Chem Lett; 2020 Sep; 30(17):127372. PubMed ID: 32738965
[TBL] [Abstract][Full Text] [Related]
12. Gankyrin: a new oncoprotein and regulator of pRb and p53.
Dawson S; Higashitsuji H; Wilkinson AJ; Fujita J; Mayer RJ
Trends Cell Biol; 2006 May; 16(5):229-33. PubMed ID: 16581249
[TBL] [Abstract][Full Text] [Related]
13. Retinoblastoma protein modulates gankyrin-MDM2 in regulation of p53 stability and chemosensitivity in cancer cells.
Qiu W; Wu J; Walsh EM; Zhang Y; Chen CY; Fujita J; Xiao ZX
Oncogene; 2008 Jul; 27(29):4034-43. PubMed ID: 18332869
[TBL] [Abstract][Full Text] [Related]
14. Gankyrin promotes the proliferation of human pancreatic cancer.
Meng Y; He L; Guo X; Tang S; Zhao X; Du R; Jin J; Bi Q; Li H; Nie Y; Liu J; Fan D
Cancer Lett; 2010 Nov; 297(1):9-17. PubMed ID: 20483533
[TBL] [Abstract][Full Text] [Related]
15. Discovery of multiple interacting partners of gankyrin, a proteasomal chaperone and an oncoprotein--evidence for a common hot spot site at the interface and its functional relevance.
Nanaware PP; Ramteke MP; Somavarapu AK; Venkatraman P
Proteins; 2014 Jul; 82(7):1283-300. PubMed ID: 24338975
[TBL] [Abstract][Full Text] [Related]
16. Gankyrin is frequently overexpressed in breast cancer and is associated with ErbB2 expression.
Kim YH; Kim JH; Choi YW; Lim SK; Yim H; Kang SY; Chung YS; Lee GY; Park TJ
Exp Mol Pathol; 2013 Apr; 94(2):360-5. PubMed ID: 23276718
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of HURP inhibits the proliferation of hepacellular carcinoma cells via downregulation of gankyrin and accumulation of p53.
Kuo TC; Chang PY; Huang SF; Chou CK; Chao CC
Biochem Pharmacol; 2012 Mar; 83(6):758-68. PubMed ID: 22230478
[TBL] [Abstract][Full Text] [Related]
18. Gankyrin: an intriguing name for a novel regulator of p53 and RB.
Lozano G; Zambetti GP
Cancer Cell; 2005 Jul; 8(1):3-4. PubMed ID: 16023592
[TBL] [Abstract][Full Text] [Related]
19. Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway.
Chen J; Bai M; Ning C; Xie B; Zhang J; Liao H; Xiong J; Tao X; Yan D; Xi X; Chen X; Yu Y; Bast RC; Zhang Z; Feng Y; Zheng W
Oncogene; 2016 May; 35(19):2506-17. PubMed ID: 26364616
[TBL] [Abstract][Full Text] [Related]
20. Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer.
Jiang Y; Iakova P; Jin J; Sullivan E; Sharin V; Hong IH; Anakk S; Mayor A; Darlington G; Finegold M; Moore D; Timchenko NA
Hepatology; 2013 Mar; 57(3):1098-106. PubMed ID: 23172628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
